ERBB2 and acute lymphoblastic leukemia: Palbociclib is known as an emerging option for patients with HR+/HER2− advanced or metastatic breast cancer, while tacrolimus and sirolimus are already extensively studied in ALL patients receiving stem cell transplantation.